ADIL
ADIAL PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$4.86
−6.72%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +34.5%
- Free cash flow
- -71.7%
- Operating cash flow
- -71.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +95.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- +39.6%
- EBIT
- +5.9%
- Net income
- +39.6%
- EPS
- +32.8%
- Free cash flow
- +6.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026